- Home
- BGH vs TSHA Comparison
BGH vs TSHA Comparison
Compare BGH & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BGH | TSHA |
|---|---|---|
| Founded | 2012 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 297.0M | 1.6B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | BGH | TSHA |
|---|---|---|
| Price | $15.15 | $5.62 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $10.22 |
| AVG Volume (30 Days) | 61.5K | ★ 3.6M |
| Earning Date | 01-01-0001 | 11-04-2025 |
| Dividend Yield | ★ 10.06% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $6,310,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.92 | $1.05 |
| 52 Week High | $14.50 | $6.02 |
Technical Indicators
Market Signals| Indicator | BGH | TSHA |
|---|---|---|
| Relative Strength Index (RSI) | 50.88 | 56.39 |
| Support Level | $15.15 | $5.58 |
| Resistance Level | $15.32 | $6.02 |
| Average True Range (ATR) | 0.13 | 0.27 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 50.00 | 48.13 |
Price Performance
Historical ComparisonAbout BGH Barings Global Short Duration High Yield Fund of Beneficial Interests
Barings Global Short Duration High Yield Fund is a diversified, closed-end management investment company. Its investment objective is to seek as high a level of current income as the Adviser determines is consistent with capital preservation.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.